ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response (pCR)
Authors: Earl, H., Hiller, L., Dunn, J., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Abraham, J., Thomas, J., Provenzano, E., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Houston, S., Rea, D., Bartlett, J., Caldas, C., Cameron, D., Hayward, L.
Conference: NCRI Cancer Conference in the Clinical Trials Showcase
Dates: 02/11/2014
Source: Manual
Preferred by: Tamas Hickish